Clinical

Dataset Information

0

Fruquintinib Plus Capecitabine Versus Bevacizumab Plus Capecitabine as Maintenance Therapy Following First-line Treatment for Metastatic Colorectal Cancer


ABSTRACT: This is an open-label, multicenter, randomized phase 2 study evaluating the efficacy and safety of fruquintinib plus capecitabine versus bevacizumab plus capecitabine as maintenance therapy following first-line treatment for metastatic colorectal cancer. Patients who have already achieved disease control (including CR/PR and SD), without discontinuation for toxicity, and are progression free after 4-6 months of standard first-line induction treatment will be assigned to 2 maintenance treatment groups by randomization in a 1:1 ratio to receive fruquintinib + capecitabine (Arm A) or bevacizumab + capecitabine (Arm B). The study contains a safety lead-in phase in which the safety and tolerability of fruquintinib + capecitabine will be assessed prior to the phase 2 portion of the study. All patients from Arm A and Arm B will be treated until progressive disease, death from any cause, unacceptable toxicity or informed consent withdrawal (whichever occurs earlier).

DISEASE(S): Colorectal Cancer,Colorectal Neoplasms

PROVIDER: 2365787 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

Similar Datasets

2023-02-17 | GSE225078 | GEO
| 3051 | ecrin-mdr-crc
| 2740471 | ecrin-mdr-crc
| 2387531 | ecrin-mdr-crc
| PRJNA933692 | ENA
2022-08-21 | GSE211373 | GEO
| 2749552 | ecrin-mdr-crc
| 2210984 | ecrin-mdr-crc
2008-01-12 | GSE8465 | GEO
2014-11-14 | E-GEOD-36864 | biostudies-arrayexpress